Cytomegalovirus in the transplant setting: Where are we now and what happens next? A report from the International CMV Symposium 2021

Transpl Infect Dis. 2022 Dec;24(6):e13977. doi: 10.1111/tid.13977. Epub 2022 Nov 11.


The CMV Symposium in September 2021 was an international conference dedicated to cytomegalovirus (CMV) infection after solid organ or hematopoietic stem cell transplantation. This review provides an overview of the presentations given by the expert faculty, supplemented with educational clinical cases. Topics discussed include CMV epidemiology and diagnosis, the burden of CMV infection and disease, CMV-specific immunity and management of CMV in transplant settings. Major advances in the prevention and treatment of CMV in the past decade and increased understanding of CMV immunity have led to improved patient outcomes. In the future, management algorithms may be individualized based on the transplant recipient's immune profile, which will mark the start of a new era for patients with CMV.

Keywords: cellular therapy; cytomegalovirus immunoglobulin (CMVIG); hematopoietic stem cell transplant; prophylaxis; solid organ transplant; treatment; vaccine.

Publication types

  • Review

MeSH terms

  • Antiviral Agents / therapeutic use
  • Cytomegalovirus
  • Cytomegalovirus Infections* / diagnosis
  • Cytomegalovirus Infections* / epidemiology
  • Cytomegalovirus Infections* / prevention & control
  • Hematopoietic Stem Cell Transplantation* / adverse effects
  • Humans
  • Lung Transplantation*
  • Organ Transplantation* / adverse effects


  • Antiviral Agents

Grants and funding